JNJ Leads Defensive Stocks as KO Surpasses SPY in 2026

The three defensive blue chips that entered 2026 promising safety have produced wildly different returns. Among them, Johnson & Johnson (JNJ) has clearly dominated with a year-to-date gain of 35%. Q2 sales at JNJ reached $25.3 billion, and the company's pipeline carried the year, particularly its oncology and immunology portfolio.

Johnson & Johnson added to its strength through its acquisition of Intra-Cellular Therapies, which brought in the Caplyta franchise. The company is also on track for a mid-2027 separation of DePuy Synthes. Meanwhile, Procter & Gamble (PG) underperformed with a 4% gain, and its fiscal Q4 delivered flat organic sales and a revenue miss.

Coca-Cola (KO), however, rode pricing power and steady global volume to a 28% year-to-date gain. The company's trademark Coca-Cola posted its strongest volume growth in 17 years excluding COVID-19 recovery, aided by FIFA World Cup activation across more than 180 markets. CEO Joaquin Duato stated JNJ has 'the strongest portfolio and pipeline in our 140-year history.'

Investors may consider owning shares of this defensive group, but the label described risk rather than return. A balanced staples-plus-healthcare mix looks like a reasonable posture heading into year-end.